| abstract |
The present invention relates to novel analogs and compositions of glucagon-like peptides that are useful for upregulating mammalian insulin expression and treating diabetes. Specifically, these peptide derivatives have peptidomimetic linkers and provide long duration of action for the treatment of diabetes and other insulinotropic peptide-related diseases, gastrointestinal function and activities related to glucagon levels. |